Clinical Commander

Back to dossier
cardio.cardiogenic-shock.after-non-cardiac-surgery.v1PRODUCTION
cardio.cardiogenic-shock.after-non-cardiac-surgery.v1

Cardiogenic shock — after non-cardiac surgery (perioperative)

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Perioperative CS = 4 candidate etiologies (MINS/perioperative MI, PE, occult CS, mechanical) developing within 7d post non-cardiac surgery; differentiate via troponin pattern, ECG, echo, CTPA timing; address underlying driver before escalating MCS

Inputs
2
Actions
0
Advance rule
Set
Advance when

Differential framed + dominant driver hypothesized

Patient inputs (10)

Tachycardia is type-2 ischemia trigger; bradycardia from BB on board may unmask CS

Post-op AKI common; eGFR for drug dosing + dabigatran/DOAC consideration per MANAGE (PMID 30340966)

Surgery type drives risk (vascular > intra-abdominal > orthopedic); post-op day (POD) drives differential — POD 0–2 (myocardial event, hemorrhage), POD 3–7 (PE peak), POD >7 (sepsis predominant)

BB withdrawal post-op is rebound risk (POISE trial framework); ASA continuation decision per POISE-2 PMID 24679062; statin continuation strongly recommended

STAT troponin within 24h post-op is core MINS screen — VISION 8–19% incidence; threshold ≥65 ng/L hs-cTnT or ≥20 ng/L hs-cTnI absolute change drives prognosis (Devereaux JAMA 2014 PMID 24686072)

Anemia is leading driver of type-2 demand mismatch in MINS; transfusion threshold 7–8 g/dL per REALITY (PMID 33667520) + TRICC framework; restrictive strategy proven non-inferior in stable patients but liberal preferred for active ischemia

STAT bedside echo for new LV/RV dysfunction, valvular issue, tamponade exclusion, fluid responsiveness assessment

STAT ECG — type-1 STEMI pattern triggers cath lab; type-2 demand mismatch usually shows non-specific changes (T-wave inversions, ST depressions)

Sustained SBP <90 / MAP <65 drives CS-trigger threshold; POISE-3 (PMID 36286687) hypotension-avoidance strategy emphasizes intra/post-op MAP ≥80

SCAI 2022 staging marker; rising lactate post-op flags CS overlap

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningperioperative_type1_stemi
    Post-op type-1 STEMI pattern (regional ST elevation + dynamic troponin + concordant wall motion) → cath lab activation despite post-op bleed risk
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningmassive_post_op_bleed_with_shock
    Surgical-site / GI / retroperitoneal bleed + hemodynamic shock → emergent surgical re-exploration + massive transfusion protocol
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpost_op_pe_with_shock
    Post-op POD 3–7 PE with hemodynamic compromise → CTPA + thrombolysis decision (systemic vs catheter-directed weighed against post-op bleed risk)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremins_with_acceptable_bleed_risk
    MINS confirmed (troponin elevation per VISION criteria) + no overt ACS pattern + bleed risk acceptable → consider dabigatran 110 BID per MANAGE
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveredo_not_initiate_de_novo_periop_bb
    Tempting to start metoprolol/BB peri-op for tachycardia or BP control → STOP, POISE harm signal (increased stroke + death)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Perioperative CS after non-cardiac surgery — driver-directed therapy (transfuse anemia, control pain, continue/initiate ASA + statin, BB selectively NOT de novo, dabigatran consideration for MINS)
axis: perioperative_cs_phenotype
Selected axis "Perioperative CS after non-cardiac surgery — driver-directed therapy (transfuse anemia, control pain, continue/initiate ASA + statin, BB selectively NOT de novo, dabigatran consideration for MINS)" by default fallback (first axis)
  • aspirin
    first line
    antiplatelet_cox1
    81 mg PO daily — CONTINUE if pre-op or INITIATE if MINS / new ACS pattern • PO • daily
    triggers: preop_asa_continuation_per_poise_2, mins_with_ischemic_pattern
    POISE-2 (PMID 24679062) — neither benefit nor harm pre-op; weigh individually. POST-op MINS or ischemia → continue/initiate per 2024 ACC/AHA Perioperative (PMID 39236235)
    rxcui 243670
  • atorvastatin
    first line
    hmg_coa_reductase_inhibitor
    40–80 mg PO daily — CONTINUE pre-op statin and INITIATE if newly diagnosed MINS/ACS • PO • daily
    triggers: mins, preop_statin_continuation, new_acs_pattern
    Strong evidence for pre-op statin continuation; initiation per 2024 ACC/AHA Perioperative (PMID 39236235); secondary prevention post-MINS
    rxcui 83367
  • norepinephrine
    first line
    alpha_beta_pressor
    0.05–0.5 µg/kg/min IV titrate to MAP ≥65 • IV • continuous
    triggers: post_op_map_below_65_after_volume_assessment
    SOAP-II first-line (PMID 20200382); maintains coronary perfusion without precipitating tachy-arrhythmia
    rxcui 7512
  • dobutamine
    second line
    beta1_inotrope
    2.5–5 µg/kg/min IV (low-dose) • IV • continuous
    triggers: low_ci_after_pressor_and_volume_optimization
    Inotropic support if CI <2.2; balance arrhythmia risk in post-op state (DOREMI PMID 33704937)
    rxcui 3616
  • carvedilol
    comorbidity specific
    nonselective_alpha_beta_blocker
    CONTINUE pre-op BB at home dose; do NOT initiate de novo per POISE PMID 18479744; if needed post-recovery, start carvedilol 3.125 mg BID titrate • PO • BID
    triggers: preop_bb_continuation, post_op_acs_or_hf_after_recovery
    POISE (PMID 18479744) — perioperative metoprolol initiation INCREASED stroke + death; CONTINUE pre-op BB; INITIATE only after recovery + indication (HFrEF, ACS, AF rate control)
    rxcui 20352
  • dabigatran
    second line
    direct_thrombin_inhibitor
    110 mg PO BID (per MANAGE PMID 30340966 dosing) — CONSIDER for MINS without overt ACS • PO • BID
    triggers: mins_without_overt_acs_with_acceptable_bleed_risk
    MANAGE 2018 (PMID 30340966) — dabigatran reduced major vascular events in MINS by 28%; weigh post-op bleed risk; avoid if CrCl <30
    rxcui 1037045
  • apixaban
    comorbidity specific
    doac_factor_xa_direct
    5 mg PO BID (or 2.5 mg BID per renal/age criteria) • PO • BID
    triggers: post_op_af_with_cha2ds2vasc_above_2, pe_treatment_post_op
    AC for new-onset AF or post-op PE; weigh against bleed risk; ACC/AHA 2023 AF guideline
    rxcui 1364430
  • furosemide
    comorbidity specific
    loop_diuretic
    20–40 mg IV (lower than HF doses to avoid over-diuresis) • IV • q12h prn
    triggers: post_op_volume_overload_with_pulmonary_edema
    Decongest post-op fluid shifts AFTER MAP stable; cautious in AKI
    rxcui 4603

outpatient playbook — drug actions (2)

  1. 1. continue secondary prevention indefinitely
    rxcui 243670
    aspirin 81 mg PO daily + atorvastatin 40–80 mg PO daily indefinitely • PO • daily
    trigger: Post-MINS or post-perioperative-MI
    2024 ACC/AHA Perioperative PMID 39236235
  2. 2. reassess dabigatran continuation at 2 years
    rxcui 1037045
    consider discontinuation vs continuation per MANAGE protocol • PO • reassess
    trigger: 2 years post-MINS
    MANAGE PMID 30340966 — 2-yr trial duration; individualize beyond

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Post-op troponin elevated within 30d of non-cardiac surgery → screen for MINS (8–19% incidence per VISION PMID 24686072); POD 0–7: SBP <90 + lactate ≥2 + hypoperfusion → perioperative CS workup; Post-op dyspnea + chest pain + tachycardia → screen for perioperative MI vs PE vs occult CS.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiogenic shock — after non-cardiac surgery (perioperative)** (cardio.cardiogenic-shock.after-non-cardiac-surgery.v1).
Scope: Perioperative CS = 4 candidate etiologies (MINS/perioperative MI, PE, occult CS, mechanical) developing within 7d post non-cardiac surgery; differentiate via troponin pattern, ECG, echo, CTPA timing; address underlying driver before escalating MCS

No severity triggers fired against current inputs.

Plan

Regimen axis: **Perioperative CS after non-cardiac surgery — driver-directed therapy (transfuse anemia, control pain, continue/initiate ASA + statin, BB selectively NOT de novo, dabigatran consideration for MINS)**.
1. aspirin 81 mg PO daily — CONTINUE if pre-op or INITIATE if MINS / new ACS pattern PO daily (antiplatelet_cox1, first line) — POISE-2 (PMID 24679062) — neither benefit nor harm pre-op; weigh individually. POST-op MINS or ischemia → continue/initiate per 2024 ACC/AHA Perioperative (PMID 39236235)
2. atorvastatin 40–80 mg PO daily — CONTINUE pre-op statin and INITIATE if newly diagnosed MINS/ACS PO daily (hmg_coa_reductase_inhibitor, first line) — Strong evidence for pre-op statin continuation; initiation per 2024 ACC/AHA Perioperative (PMID 39236235); secondary prevention post-MINS
3. norepinephrine 0.05–0.5 µg/kg/min IV titrate to MAP ≥65 IV continuous (alpha_beta_pressor, first line) — SOAP-II first-line (PMID 20200382); maintains coronary perfusion without precipitating tachy-arrhythmia
4. dobutamine 2.5–5 µg/kg/min IV (low-dose) IV continuous (beta1_inotrope, second line) — Inotropic support if CI <2.2; balance arrhythmia risk in post-op state (DOREMI PMID 33704937)
5. carvedilol CONTINUE pre-op BB at home dose; do NOT initiate de novo per POISE PMID 18479744; if needed post-recovery, start carvedilol 3.125 mg BID titrate PO BID (nonselective_alpha_beta_blocker, comorbidity specific) — POISE (PMID 18479744) — perioperative metoprolol initiation INCREASED stroke + death; CONTINUE pre-op BB; INITIATE only after recovery + indication (HFrEF, ACS, AF rate control)
6. dabigatran 110 mg PO BID (per MANAGE PMID 30340966 dosing) — CONSIDER for MINS without overt ACS PO BID (direct_thrombin_inhibitor, second line) — MANAGE 2018 (PMID 30340966) — dabigatran reduced major vascular events in MINS by 28%; weigh post-op bleed risk; avoid if CrCl <30
7. apixaban 5 mg PO BID (or 2.5 mg BID per renal/age criteria) PO BID (doac_factor_xa_direct, comorbidity specific) — AC for new-onset AF or post-op PE; weigh against bleed risk; ACC/AHA 2023 AF guideline
8. furosemide 20–40 mg IV (lower than HF doses to avoid over-diuresis) IV q12h prn (loop_diuretic, comorbidity specific) — Decongest post-op fluid shifts AFTER MAP stable; cautious in AKI

Setting playbook (outpatient) — Long-term post-MINS surveillance: secondary prevention maintenance, future-surgery cardiac risk stratification (RCRI + history), cardiac rehab completion, mental health continuity, dabigatran discontinuation decision per MANAGE 2-yr framework
9. continue secondary prevention indefinitely aspirin 81 mg PO daily + atorvastatin 40–80 mg PO daily indefinitely PO daily — Post-MINS or post-perioperative-MI (2024 ACC/AHA Perioperative PMID 39236235)
10. reassess dabigatran continuation at 2 years consider discontinuation vs continuation per MANAGE protocol PO reassess — 2 years post-MINS (MANAGE PMID 30340966 — 2-yr trial duration; individualize beyond)

Non-pharmacologic actions:
- Annual flu + COVID + pneumococcal vaccines
- Cardiac rehab maintenance phase
- Mental health follow-up
- Future surgery: comprehensive pre-op cardiac evaluation including stress test/imaging if symptoms; share decision-making about elective procedures

AVOID / contraindication checks:
- Do_NOT_initiate_de_novo_bb_periop (POISE PMID 18479744 — increased stroke + death)
- Aggressive_BP_lowering_AVOID (POISE — hypotension is dominant driver of MINS)
- Fluid_bolus_AVOID_without_preload_responsiveness_assessment (FENICE methodology)
- Dabigatran_avoid_if_CrCl_below_30 (MANAGE PMID 30340966 + drug label)
- Thrombolysis_relative_CI_recent_surgery (case by case for massive PE)
- High_dose_dobutamine_AVOID_post_op_arrhythmia_risk (DOREMI)
- Aspirin_CONTINUATION_individualized_per_POISE_2 (PMID 24679062 — neither benefit nor harm pre op)

Monitoring

Regimen monitoring:
- arterial line continuous BP (post-op standard)
- central venous access (CS bundle)
- serial troponin q6h x 24h post event (MINS surveillance)
- lactate q1 2h until clearing (CardShock framework)
- daily echo for lv recovery (ESC 2021)
- continuous ecg telemetry (post-op AF + arrhythmia surveillance)
- surgical site for re bleed (POISE-3 framework)
- hgb q4 6h initially to titrate transfusion threshold (REALITY PMID 33667520)
- CTPA if PE suspected (post-op DVT risk elevated)

Setting (outpatient) monitoring:
- Annual cardiology visits
- Echo only if symptomatic or residual dysfunction
- Bleeding surveillance if on AC

Follow-up plan: MINS triggers post-op cardiology follow-up at 30d (high 30-d mortality 9.8% per VISION); secondary prevention initiation (ASA, statin, BB, ACEi as appropriate); cardiac rehab; re-evaluate AC strategy per MANAGE; pre-op risk stratification for future surgeries
- Close-out criterion: Post-MINS plan + secondary prevention initiated

Monitoring phase: A-line + central line; serial troponin q6h × 24h post-event; lactate q1–2h until clearing; daily echo; continuous ECG; daily BMP; surgical-site monitoring (re-bleed risk)

Disposition

Current setting: outpatient — Long-term post-MINS surveillance: secondary prevention maintenance, future-surgery cardiac risk stratification (RCRI + history), cardiac rehab completion, mental health continuity, dabigatran discontinuation decision per MANAGE 2-yr framework

Disposition criteria:
- Long-term continuation; cross-link to chronic CAD/HF engines if indicated

Escalation triggers (move to higher acuity):
- New ACS symptoms → urgent ED + ACS pathway
- Future surgery planning → high-risk cardiac eval (RCRI + MINS history)
- Bleeding on AC → reversal + reassessment

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Post-op type-1 STEMI pattern (regional ST elevation + dynamic troponin + concordant wall motion) → cath lab activation despite post-op bleed risk
- [LIFE_THREATENING] Surgical-site / GI / retroperitoneal bleed + hemodynamic shock → emergent surgical re-exploration + massive transfusion protocol
- [LIFE_THREATENING] Post-op POD 3–7 PE with hemodynamic compromise → CTPA + thrombolysis decision (systemic vs catheter-directed weighed against post-op bleed risk)

Citations

- 2024 ACC/AHA Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery (Thompson Circulation 2024, PMID 39236235) + ESC 2022 Non-cardiac Surgery Cardiovascular Guideline + SCAI 2022 CS staging (Naidu PMID 35718438) + 2022 AHA/ACC/HFSA HF Guideline (PMID 35363499) [PMID:39236235](https://pubmed.ncbi.nlm.nih.gov/39236235/)
- Cited evidence (PMID 24686072) [PMID:24686072](https://pubmed.ncbi.nlm.nih.gov/24686072/)
- Cited evidence (PMID 30340966) [PMID:30340966](https://pubmed.ncbi.nlm.nih.gov/30340966/)
- Cited evidence (PMID 18479744) [PMID:18479744](https://pubmed.ncbi.nlm.nih.gov/18479744/)
- Cited evidence (PMID 24679062) [PMID:24679062](https://pubmed.ncbi.nlm.nih.gov/24679062/)

Last reconciled with current guidelines: 2026-05-14.
References
  • 2024 ACC/AHA Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery (Thompson Circulation 2024, PMID 39236235) + ESC 2022 Non-cardiac Surgery Cardiovascular Guideline + SCAI 2022 CS staging (Naidu PMID 35718438) + 2022 AHA/ACC/HFSA HF Guideline (PMID 35363499) — PMID:39236235
  • Cited evidence (PMID 24686072) — PMID:24686072
  • Cited evidence (PMID 30340966) — PMID:30340966
  • Cited evidence (PMID 18479744) — PMID:18479744
  • Cited evidence (PMID 24679062) — PMID:24679062